Adalvo is proud to announce the successful launch of Desmopressin Sublingual Tablets in France, solidifying our position as the first generic to introduce this innovative medication in the European Union. This accomplishment represents a significant milestone in our strategic partnership with a key collaborator.
Our niche peptide product has been developed based on the reference brand Minirin Melt from Ferring which is indicated for the treatment of diabetes insipidus, primary nocturnal enuresis and nocturia. The brand sold $116Mn globally in 2022, according to IQVIA.
This launch not only strengthens Adalvo's pharmaceutical portfolio but also reinforces the company's dedication to addressing the diverse needs of patients and healthcare providers.
The collaborative effort with our strategic partner reflects Adalvo's continuous pursuit of excellence in delivering high-quality and innovative pharmaceutical solutions. As we celebrate the successful introduction of Desmopressin in France, Adalvo looks forward to further expanding its presence and making a positive impact on patient care in the dynamic healthcare landscape.
Partner up now!
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
paulo.rodriguez@adalvo.com – Europe
marta.puig@adalvo.com - South Europe
marc.nolasco@adalvo.com - West Europe
jose.rendueles@adalvo.com- North Europe, CEE & APAC
supreet.sharma@adalvo.com – North America & Canada
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
bruno.alves@adalvo.com - Brazil & MENA
ajish.rajan@adalvo.com – Brands & Specialty Products
arni.baldursson@adalvo.com - Head of Global BD&L
Click on your preferred Business Partner and get in touch today!